CERC - Cerecor gains on CERC-002 data in mid-stage COVID-19 study

Cerecor ([[CERC]] +13.6%) announces results from its exploratory Phase 2 proof of concept trial of monoclonal antibody CERC-002 in patients hospitalized with COVID-19 associated pneumonia and mild-to-moderate acute respiratory distress syndrome.The trial included 83 patients who were randomized 1:1 to receive standard of care at the sites plus either a single dose of 1,200 mg of CERC-002 or placebo subcutaneously.The trial demonstrated robust improvement in the primary endpoint ((proportion of patients alive and free of respiratory failure over the 28-day study period)) compared to placebo.Subgroup analysis of patients 60 years of age showed that CERC-002 treatment led to a greater than 3-fold increase in likelihood of avoiding respiratory failure and death compared to placebo.No drug-related serious adverse effects were reported in the trial, and there was no increase in infections in CERC-002 treated patients.Cerecor intends to meet with the FDA in a bid to initiate a registration trial and file for Breakthrough

For further details see:

Cerecor gains on CERC-002 data in mid-stage COVID-19 study